SURMOUNT-1 demonstrated 20.9% weight loss at 15 mg, nearly double orforglipron's 12.4%
For women unable or unwilling to take HRT , several alternatives exist: Fezolinetant : a neurokinin-3 receptor antagonist specifically licensed for moderate to severe vasomotor symptoms, offering a non-hormonal option [19] [20] Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs): medications such as venlafaxine, citalopram, or fluoxetine may reduce hot flash frequency, though efficacy varies
The dose are oral vitamin C (500 mg twice daily) and melatonin (24 mg nightly)
Journal of Environmental Management, 256 , 109894
Cellular contents of reduced glutathione (GSH) and oxidised glutathione (GSSG), was disturbed upon NiO-NP exposure
Oral GLP-1s Finally Break the Needle Barrier The most meaningful development shaping the GLP-1 category in 2026 is the arrival of oral therapies for chronic weight management